New
HealthMore in Health→
FDA peptide review puts a booming wellness market under new scrutiny
Key Takeaways
- An FDA-convened panel is reviewing whether seven peptides should be recommended for compounding.
- Doctors cited in the source say clinical evidence is still too limited to establish safety and effectiveness.
- Supporters argue restrictions have pushed buyers toward gray-market suppliers with little oversight.
- Critics say the composition of the advisory panel itself has become part of the controversy.
DE
DT Editorial Team··via medicalxpress.com
